Glycominds Ltd.

Other

University of California

Katholieke Universiteit Leuven

Avinoam Dukler

Nir Dotan

Mikael Schwarz

Charalabos Pothoulakis

Severine Vermeire

Hon Wai Koon

Jennifer Yarden

Rom T Altstock

Mikael Scwartz

Ari Gargir

Randy Ringold

Magali De Bruyn

Ghislain Opdenakker

Mucosal healing is an indication to the disease activity level in patients affected by inflammatory bowel diseases, and it is thus far mainly monitored by endoscopy. Instead or in addition to endoscopy, the invention provides blood test using biomarkers and an index that allows a practitioner to assess the status of mucosal healing, to change or adapt dosage of treatment and to predict which patient will become responder versus non-responder to treatment as assessed by endoscopy. While none of neutrophils cell count, c-reactive protein (CRP), Human type of Cathelicidin (LL-37), or Chitinase 3-like 1 (CHI3L1) alone is able to provide an assessment means of mucosal healing, the invention provides a novel combination of the levels of these biomarkers to assess the level of mucosal healing in relation to endoscopic healing.

Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis

Method of diagnosing and treating inflammatory bowel disease are disclosed herein. Inflammatory bowel disease can be treated and diagnosed using cathelicidin peptides and detection agents thereof. Specifically, method of treating and diagnosing Crohn's disease and ulcerative colitis are disclosed herein.

Inflammatory bowel disease markers and therapies for colitis-associated intestinal fibrosis

Disclosed is a method for diagnosing and prognosing multiple sclerosis and more particularly to a method for diagnosing and prognosing multiple sclerosis by measuring levels of antibodies. The levels of IgM-type anti-Glc(&#x3b1;1,2)Glc(&#x3b1;) or Glc(&#x3b1;1,3)Glc(&#x3b1;) or Glc(&#x3b1;1,6)Glc(&#x3b1;) antibodies in serum act as diagnostic markers for MS disease and as prognostic biomarkers for the conversion of CIS patients suggestive of MS to clinically definite MS (CDMS) within 24 months.

Method for diagnosing multiple sclerosis

This application is related to immunoassay reagent compositions comprising a glycan reagent for diagnosing multiple sclerosis.

Immunoassay reagent compositions for diagnosing multiple sclerosis

The invention relates to methods and reagents for diagnosing and assessing the prognosis of multiple sclerosis.

Method for evaluating risk in multiple sclerosis

Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample.

Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.

Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease

Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample.

Method for diagnosing diseases based on levels of anti-glycan antibodies

The present invention provides methods of utilizing a complex carbohydrate library which includes a plurality of complex carbohydrate structures each being attached to a specific site of a solid support such as a platform for screening and isolating complex carbohydrate structures capable of specifically and uniquely binding with an entity such as a polypeptide.

Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof

The present invention provides a complex carbohydrate library which includes a plurality of complex carbohydrate structures each being attached to a specific site of a solid support such as a platform, thereby making each of the plurality of complex carbohydrate structures uniquely addressable. The addressable nature of the complex carbohydrate library of the present invention makes it particularly suitable for screening and isolating molecules that bind specifically and uniquely to complex carbohydrate structures associated with various disorders and conditions, thus enabling identification of new drugs candidates.

Growing community of inventors

Moddi'in, Israel

Avinoam Dukler